CD8A and melanoma: Similarly, in a melanoma mouse model, CTLA-4 blockade cooperated with radiotherapy to increase the CD8 effector T cell to Treg ratio and diversify the T cell receptor (TCR) repertoire resulting in therapeutic synergy.